Danish pharmaceutical company Novo Nordisk plunged 21% on the Copenhagen stock exchange after announcing the main results of the Redefine-1 study, according to a press release.
The stock is now heading for its worst trading day since April 2002.
“When evaluating treatment effects if all subjects completed treatment1, subjects treated with Cagrisema achieved 22.7% greater weight loss after 68 weeks, compared to a reduction of 11 .8% with cagrilintide 2.4 mg, 16.1% with semaglutide 2.4 mg and 2.3% with placebo alone. Patients treated with Cagrisema experienced weight loss of 25% or more after 68 weeks, compared to 6.0% with cagrilintide 2.4 mg, 16.2% with semaglutide 2.4 mg, and 0.9% with placebo.
Redefine-1 is a phase 3 study that compares Cagrisema administered subcutaneously to the individual components cagrilintide 2.4 mg, semaglutide 2.4 mg, and placebo, all administered once weekly.
“The study included 3,417 randomized individuals, obese or overweight, with one or more comorbidities and a mean weight of 106.9 kg at the start of the study. The study achieved its primary objective by demonstrating weight loss. statistically significant and greater weight at week 68 with Cagrisema compared to placebo,” writes Novo.
